Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer

Abstract Heparanase promotes tumor growth in breast tumors. We now evaluated heparanase protein and gene-expression status and investigated its impact on disease-free survival in order to gain better insight into the role of heparanase in ER-positive (ER+) breast cancer prognosis and to clarify its...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tamar Zahavi, Mali Salmon-Divon, Roberto Salgado, Michael Elkin, Esther Hermano, Ariel M. Rubinstein, Prudence A. Francis, Angelo Di Leo, Giuseppe Viale, Evandro de Azambuja, Lieveke Ameye, Christos Sotiriou, Asher Salmon, Nataly Kravchenko-Balasha, Amir Sonnenblick
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/637b2a9596934ef69ef658839f8718ad
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:637b2a9596934ef69ef658839f8718ad
record_format	dspace
spelling	oai:doaj.org-article:637b2a9596934ef69ef658839f8718ad2021-12-02T15:49:26ZHeparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer10.1038/s41523-021-00277-x2374-4677https://doaj.org/article/637b2a9596934ef69ef658839f8718ad2021-05-01T00:00:00Zhttps://doi.org/10.1038/s41523-021-00277-xhttps://doaj.org/toc/2374-4677Abstract Heparanase promotes tumor growth in breast tumors. We now evaluated heparanase protein and gene-expression status and investigated its impact on disease-free survival in order to gain better insight into the role of heparanase in ER-positive (ER+) breast cancer prognosis and to clarify its role in cell survival following chemotherapy. Using pooled analysis of gene-expression data, we found that heparanase was associated with a worse prognosis in estrogen receptor-positive (ER+) tumors (log-rank p < 10−10) and predictive to chemotherapy resistance (interaction p = 0.0001) but not hormonal therapy (Interaction p = 0.62). These results were confirmed by analysis of data from a phase III, prospective randomized trial which showed that heparanase protein expression is associated with increased risk of recurrence in ER+ breast tumors (log-rank p = 0.004). In vitro experiments showed that heparanase promoted tumor progression and increased cell viability via epithelial–mesenchymal transition, stemness, and anti-apoptosis pathways in luminal breast cancer. Taken together, our results demonstrated that heparanase is associated with worse outcomes and increased cell viability in ER+ BC.Tamar ZahaviMali Salmon-DivonRoberto SalgadoMichael ElkinEsther HermanoAriel M. RubinsteinPrudence A. FrancisAngelo Di LeoGiuseppe VialeEvandro de AzambujaLieveke AmeyeChristos SotiriouAsher SalmonNataly Kravchenko-BalashaAmir SonnenblickNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 7, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Tamar Zahavi Mali Salmon-Divon Roberto Salgado Michael Elkin Esther Hermano Ariel M. Rubinstein Prudence A. Francis Angelo Di Leo Giuseppe Viale Evandro de Azambuja Lieveke Ameye Christos Sotiriou Asher Salmon Nataly Kravchenko-Balasha Amir Sonnenblick Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer
description	Abstract Heparanase promotes tumor growth in breast tumors. We now evaluated heparanase protein and gene-expression status and investigated its impact on disease-free survival in order to gain better insight into the role of heparanase in ER-positive (ER+) breast cancer prognosis and to clarify its role in cell survival following chemotherapy. Using pooled analysis of gene-expression data, we found that heparanase was associated with a worse prognosis in estrogen receptor-positive (ER+) tumors (log-rank p < 10−10) and predictive to chemotherapy resistance (interaction p = 0.0001) but not hormonal therapy (Interaction p = 0.62). These results were confirmed by analysis of data from a phase III, prospective randomized trial which showed that heparanase protein expression is associated with increased risk of recurrence in ER+ breast tumors (log-rank p = 0.004). In vitro experiments showed that heparanase promoted tumor progression and increased cell viability via epithelial–mesenchymal transition, stemness, and anti-apoptosis pathways in luminal breast cancer. Taken together, our results demonstrated that heparanase is associated with worse outcomes and increased cell viability in ER+ BC.
format	article
author	Tamar Zahavi Mali Salmon-Divon Roberto Salgado Michael Elkin Esther Hermano Ariel M. Rubinstein Prudence A. Francis Angelo Di Leo Giuseppe Viale Evandro de Azambuja Lieveke Ameye Christos Sotiriou Asher Salmon Nataly Kravchenko-Balasha Amir Sonnenblick
author_facet	Tamar Zahavi Mali Salmon-Divon Roberto Salgado Michael Elkin Esther Hermano Ariel M. Rubinstein Prudence A. Francis Angelo Di Leo Giuseppe Viale Evandro de Azambuja Lieveke Ameye Christos Sotiriou Asher Salmon Nataly Kravchenko-Balasha Amir Sonnenblick
author_sort	Tamar Zahavi
title	Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer
title_short	Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer
title_full	Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer
title_fullStr	Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer
title_full_unstemmed	Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer
title_sort	heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/637b2a9596934ef69ef658839f8718ad
work_keys_str_mv	AT tamarzahavi heparanaseapotentialmarkerofworseprognosisinestrogenreceptorpositivebreastcancer AT malisalmondivon heparanaseapotentialmarkerofworseprognosisinestrogenreceptorpositivebreastcancer AT robertosalgado heparanaseapotentialmarkerofworseprognosisinestrogenreceptorpositivebreastcancer AT michaelelkin heparanaseapotentialmarkerofworseprognosisinestrogenreceptorpositivebreastcancer AT estherhermano heparanaseapotentialmarkerofworseprognosisinestrogenreceptorpositivebreastcancer AT arielmrubinstein heparanaseapotentialmarkerofworseprognosisinestrogenreceptorpositivebreastcancer AT prudenceafrancis heparanaseapotentialmarkerofworseprognosisinestrogenreceptorpositivebreastcancer AT angelodileo heparanaseapotentialmarkerofworseprognosisinestrogenreceptorpositivebreastcancer AT giuseppeviale heparanaseapotentialmarkerofworseprognosisinestrogenreceptorpositivebreastcancer AT evandrodeazambuja heparanaseapotentialmarkerofworseprognosisinestrogenreceptorpositivebreastcancer AT lievekeameye heparanaseapotentialmarkerofworseprognosisinestrogenreceptorpositivebreastcancer AT christossotiriou heparanaseapotentialmarkerofworseprognosisinestrogenreceptorpositivebreastcancer AT ashersalmon heparanaseapotentialmarkerofworseprognosisinestrogenreceptorpositivebreastcancer AT natalykravchenkobalasha heparanaseapotentialmarkerofworseprognosisinestrogenreceptorpositivebreastcancer AT amirsonnenblick heparanaseapotentialmarkerofworseprognosisinestrogenreceptorpositivebreastcancer
_version_	1718385693729751040

Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer

Ejemplares similares